TSE:MFC

Manulife Financial (MFC.TO)

57.04
+0.49 (0.87%)
as of Jun 25, 2026, 8:00:00 pm Market Open.
1634 watching
0
Investor Insights
star iconJun 25, 2026, 12:00 am

This summary was created by AI, based on 28 opinions in the last 12 months.

Manulife Financial (MFC) has garnered mixed opinions from market experts. Many analysts recognize MFC's potential, particularly highlighting its growth in Asia and successful capital generation from legacy businesses. The consensus seems to indicate a solid long-term investment due to its steady dividend yield, with several experts suggesting that patience may be required as the stock navigates short-term fluctuations. Despite some concerns about past performance and market positioning against competitors, the company's strategy and management is viewed positively. Analysts mention the current valuation as reasonable compared to peers, suggesting MFC is a better option for income rather than growth. Overall, there is a cautious optimism about MFC's capabilities and future direction.

consensus icon
Consensus
Hold
valuation icon
Valuation
Fair Value
review icon
Similar
SLF-T
BUY
No inside information, but regulator has shut down the issue in the court case, to Manulife's benefit. Canadian insurance companies are very cheap. Manulife has great assets in Asia and US. Sees 10% earnings growth in next couple of years. Compelling, will benefit with rising rates.
WAIT
They hired a new CEO in the last 12 months. They want to grow the wealth management business. There was a short report on them a couple of weeks ago. They are doing a good job and he likes the direction they are going. They are looking at cost savings and driving efficiencies.
BUY
vs. Sunlife Q3 beat--earnings were way up. Double-digit growth in the US. Asia operations were a lower weak. 4% EPS growth only. Pricey vs. peers. Manulife has a better growth rate, and he prefers MFC. The lawsuit they face--MFC will be okay.
DON'T BUY
Earnings looked good. They freed up capital for buybacks. Interest rate hikes are positive, but might take time to come through. Product sales are good in Asia, so fundamentally in good shape. Overhang of US lawsuits, which will go on for a while. Negative Canadian bias from outside of Canada. Stock won’t move until things get cleaned up. Prefers the banks.
PAST TOP PICK
(A Top Pick Aug 16/18, Down 10%) MFC will survive the legal issue in respect to the hedge fund report. It's an extremely strong company. Likes it, though he isn't adding to it now. It's suffering with its Asian operations because of US-China trade tensions. Those will lift, then we'll see growth in MFC's Asian operations. Look beyond the headlines, which can make an erratic ride.
WEAK BUY
He has SLF-T and two US lifecos. He avoided MFC-T because of legacy products that he had issues with, as well as legacy acquisitions. They are starting to address them one at a time. He likes lifecos but you could own this one.
DON'T BUY
Owns SunLife instead. Interest rates are rising and pressuring these stocks. He likes MFC's exposure to Asia, which will help them long term. But MFC has been sideways. He needs to see MFC to rise far above its 200-day moving average before stepping in. Pays a 4.7% dividend, but little dividend growth.
TOP PICK
It ran into a short-seller and a lawsuit, but the courts have since sided with MFC. The short-seller was taking advantage in MFC and they appear to have been beaten back. MFC itself has been beaten down and is now swinging back, so buy this now. 4.6% dividend. (Analysts’ price target is $29.34)
PAST TOP PICK
(A Top Pick Nov 23/18, Down 13%) A particular investor has been complaining on courts. Apparently it is going to go on the company's favor. He thinks that the stock is oversold and is going to come back. He just bought it.
COMMENT

He doesn't know what the odds are of MFC winning this lawsuit that a hedge fund has trumpeted, but the case is a huge cloud. Rising interest rates will benefit all insurance companies whose stock prices haven't moved much but are paying fat dividend yields. MFC pays a 4.2% dividend. Maybe MFC isn't his top idea in this sector, but the problem with all the insurance companies is that they have so many policies with many many details--it's opaque, so what do they mean? And this has led to this lawsuit.

WATCH

It's been hammered because of this lawsuit and report by a short-seller. Normally this would be a buy based on valuation. There's a tiny chance that MFC will lose this case. That said, he'll wait for the decision before buying this. The judgement may pass in late-2018 or early-2019.

BUY

It's a little scary because it involves a lawsuit, which MFC considers unfounded. Anything can happen at a trial. But he feels that case law and common sense clearly support MFC. The good news it that they will clear their shorts. The lawsuit and short report have hid the fact that MFC has been showing better consistency. He see 9% share and dividend growth trading 7.2x earnings. If you own a lot of this, don't add to be safe. If you don't, yes you can buy it. He believes Manulife will clear this hurdle.

BUY

MFC has often been his top pick. For lifecos operating in the U.S. there are accouting issues between Canada and America in how they account for reserves. There is embedded value in MFC's long-term care assets that aren't reflected in the stock price. Now is a buying opportunity. He expects their next report to be fine.

TOP PICK

Sometimes people run for cover when there's a short-seller. In this case, the short-seller has picked up on a lawsuit over a 20-year-old insurance policy which he thinks doesn't have merit. The market has sold first and asked questions
later. After the pullback, the stock has regained 15% and has created a great entry point now. Trading at 1x book value, deeply discounted. 12% ROE, so profitability is solid. Geographically diverse between Canada-U.S.-Asia. Their
welath and asset management division is their golden child, growing nicely. The only weakness is their US legacy business, but they're cleaning it up. The stock should be much higher. (4.36% dividend, Analysts Price Target $29.59)

DON'T BUY

It's hard making money owning it. He's not sure why Canadians keep banging their head buying MFC, when you can buy the Canadian banks. He has no specific criticism about MFC, and in fact MFC is doing a lot of things right, like
moving more into wealth management and performing well in Asia, while diversifying away from insurance. But there's a disconnect in what they're doing and the share price, which has been ongoing.

Showing 451 to 465 of 2,281 entries